Quantcast

Latest drug discovery Stories

2014-08-14 08:28:34

ROCKVILLE, Md., Aug. 14, 2014 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, today reported financial results for the three and six months ended June 30, 2014. http://photos.prnewswire.com/prnvar/20140706/124566 CASI reported a net loss for the second quarter of 2014 of ($1.6 million), or ($0.06) per share. This compares with a net loss of ($1.9 million), or...

2014-08-14 08:28:23

-- Expanded Data from Phase II MS Trial to be Released Next Month; Plans on Course to Advance C. difficile and C-IBS Programs into the Clinic During 2014 -- ROCKVILLE, Md., Aug. 14, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, today reported financial results for the three and six months ended June 30, 2014, and provided an operational...

2014-08-12 23:09:28

In support of the Alliance for Clinical Research Excellence and Safety (ACRES) global collaborative model, industry stakeholders have pledged more than $102M in technologies and services to transform the clinical research enterprise and accelerate medicines development, enhancing quality, safety and long-term industry sustainability. (PRWEB) August 12, 2014 Following the recent meeting of a multi-sector global stakeholder consultation on clinical research site-excellence, strategic allies...

2014-08-12 08:29:26

Array planning for potential return of MEK inhibitor BOULDER, Colo., Aug. 12, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the fourth quarter and full year of its fiscal year ending June 30, 2014. http://photos.prnewswire.com/prnvar/20121029/LA02195LOGO Ron Squarer, Chief Executive Officer of Array, noted, "The Array-invented MEK inhibitors, binimetinib and selumetinib, are currently enrolling six Phase 3 trials, and each of our partners has...

2014-08-11 23:04:30

New partnership will give better clinical trial access and information to over 100,000 patient influencers. Boston and London (PRWEB) August 11, 2014 TrialReach, the world’s largest provider of clinical research information and patient-clinical trial matching, today announced a new collaboration with WEGO Health, a social network comprised of over 100,000 patient influencers. WEGO Health will expand its TrialShare platform by incorporating TrialReach tools and resources directly so that...

2014-08-11 20:23:57

LONDON, Aug. 11, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Glomerulonephritis-Pipeline Insights, 2014https://www.reportbuyer.com/product/2278516/-Glomerulonephritis-Pipeline-Insights-2014.htmlSUMMARYDelveInsight's, "Glomerulonephritis-Pipeline Insights, 2014", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under...

2014-08-11 16:25:35

LONDON, Aug. 11, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Spasticity Global Clinical Trials Review, H2, 2014https://www.reportbuyer.com/product/2280943/Spasticity-Global-Clinical-Trials-Review-H2-2014.htmlSpasticity Global Clinical Trials Review, H2, 2014SummaryGlobalData's clinical trial report, "Spasticity Global Clinical Trials Review, H2, 2014" provides data on the Spasticity clinical trial scenario. This report provides elemental information and...

2014-08-11 16:25:21

LONDON, Aug. 11, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Renal Pain Global Clinical Trials Review, H2, 2014https://www.reportbuyer.com/product/703965/Renal-Pain-Global-Clinical-Trials-Review-H2-2014.htmlRenal Pain Global Clinical Trials Review, H2, 2014SummaryGlobalData's clinical trial report, "Renal Pain Global Clinical Trials Review, H2, 2014" provides data on the Renal Pain clinical trial scenario. This report provides elemental information and...

2014-08-11 12:27:30

FRONTIER SCIENTIFIC ACQUIRES PREMIER AG INDUSTRY SUPPLIER LOGAN, Utah, Aug. 11, 2014 /PRNewswire/ -- Frontier Scientific, Inc. (FSI) announces the expansion of its agricultural products offering through the acquisition of a leading supplier of insect products to provide researchers proven quality solutions for insecticide compound screening, seed development and crop protection. Agricultural expansion is a natural fit for FSI's established areas of expertise in complex supply...

2014-08-11 08:28:49

SAN DIEGO, Aug. 11, 2014 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, today announced that Scott Pancoast, president and CEO, will present at the 34th Annual Canaccord Genuity Growth Conference on Wednesday, August 13, 2014 at 5:00 p.m. Eastern Time in Boston. The live webcast presentation and replay will be available by visiting the Investor section of the Lpath website at www.Lpath.com. About Lpath San Diego-based Lpath,...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'